Trending...
- Obey God Clothing Launches Urban Christian Apparel Line Serving All Ages
- Zivra AI Launches Real-Time Business Health and Financial Intelligence for SMEs
- The New Monaco of the South (of Italy)
AVENTURA, Fla. - PennZone -- Dr. Jeff Gelblum, Neurologist at First Choice Neurology, has brought together clinical, imaging, and laboratory capabilities to provide rapid diagnosis and treatment to individuals suffering from Alzheimer's disease.
The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.
Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.
He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."
More on The PennZone
Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.
Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy. This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."
For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.
His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.
Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.
More on The PennZone
Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."
He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.
About Jeffrey Gelblum, MD, FAAN
Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.
Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.
He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."
More on The PennZone
- New Report Reveals Surprising Trends in Illinois Airport Accidents
- PebblePad Acquires myday to Deliver Unified Digital Campus Experiences for Student Success
- Adam Clermont Releases New Book – Profit Before People: When Corporations Knew It Was Dangerous and Sold It Anyway
- Dirty Heads, 311, Tropidelic, and The Movement to Headline Everwild Music Festival in 2026 with its largest lineup to date!
- VIP Vacations Honored by Lomas as One of Top Overall Travel Agencies
Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.
Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy. This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."
For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.
His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.
Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.
More on The PennZone
- The Stork Foundation Announces 2025 Year-End Impact and Grant Awards Amid Rising National Demand
- Stout Industrial Technology Appoints Paul Bonnett as Chief Executive Officer
- Revenue Optics Appoints Ljupco Icevski as Executive Advisor in Strategic Move to Accelerate Commercial Development
- Syntax of Sorrow: An Exhibition Examining Synthetic Affliction in the Age of Artificial Intelligence
- Waarom brand mentions in ChatGPT steeds belangrijker worden
Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."
He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.
About Jeffrey Gelblum, MD, FAAN
Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
Source: First Choice Neurology
Filed Under: Health
0 Comments
Latest on The PennZone
- Lineus Medical Completes UK Registration for SafeBreak® Vascular
- Canyons & Chefs Announces Revamped Homepage
- $140 to $145 Million in 2026 Projected and Profiled in New BD Deep Research Report on its Position in $57 Billion US Marine Industry; N Y S E: OTH
- Really Cool Music Releases Its Fourth Single - "So Many Lost Years"
- MGN Logistics Acquires Fast Service LLC, Fueling MyMGN Marketplace Expansion and Supercharging Expedited Coverage Nationwide
- The Wait is Over: Salida Wine Festival Announces Triumphant 2026 Return After Seven-Year Hiatus
- Graduates With $40K in Student Debt Are Buying Businesses Instead of Taking Entry-Level Jobs
- Anne Seidman: Within the Lines
- How Democrats Made Healthcare More Expensive in 2026
- Inkdnylon Launches Bilingual Ask Inkdnylon Platform
- JS Gallery Brings Global Voices to LA Art Show 2026 with "OFF SCRIPT" Exhibition
- ANTOANETTA Partners With Zestacor Digital Marketing to Expand Online Presence for Handcrafted Luxury Jewelry
- Mitchell Sipus Releases New Dance Single "Can U"
- FrostSkin Launches Kickstarter Campaign for Patent-Pending Instant-Chill Water Purification Bottle
- The New Monaco of the South (of Italy)
- OctoNerv Completes Functional Prototype of Electronic Breast Nipple Implant (EBNI)
- Zivra AI Launches Real-Time Business Health and Financial Intelligence for SMEs
- Obey God Clothing Launches Urban Christian Apparel Line Serving All Ages
- PA Golf Cart World Launches NEV Pre-Inspection & Compliance Service for 2026
- Dr. Curtis Rasmussen Shares Leadership and AI Insights on Lead Empowered TV